Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
about
The expression of the ubiquitin ligase subunit Cks1 in human breast cancerAcetylation-dependent regulation of Skp2 functionAndrogen depletion induces senescence in prostate cancer cells through down-regulation of Skp2Skp2: a novel potential therapeutic target for prostate cancerDeregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancerDeregulation of p27 by oncogenic signaling and its prognostic significance in breast cancerB.E.A.R. GeneInfo: a tool for identifying gene-related biomedical publications through user modifiable queriesInhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapyAPC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathwayDysregulation of ubiquitin ligases in cancerExpression of TYMS in lymph node metastasis from low-grade glioma.Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma.Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cellsTargeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumorsEzetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomasDetermining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2.Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.Relation of overexpression of S phase kinase-associated protein 2 with reduced expression of p27 and PTEN in human gastric carcinoma.SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells.The mTOR inhibitor rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells.Expression of ERG protein in prostate cancer: variability and biological correlates.SCF Fbx4/alphaB-crystallin cyclin D1 ubiquitin ligase: a license to destroy.Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression.The APC/C Ubiquitin Ligase: From Cell Biology to TumorigenesisSkp2 expression unfavorably impacts survival in resectable esophageal squamous cell carcinoma.The E3 ubiquitin ligase skp2 regulates neural differentiation independent from the cell cycle.Expressions and clinical significance of factors related to giant cell tumor of bone.Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.Small molecule therapeutics targeting F-box proteins in cancer.
P2860
Q21195244-D49F586D-F1C5-4147-AF5D-D03A38A78ACAQ24292805-76B81BEC-95E5-45EE-B5E8-5C94DDA5F2FAQ24614665-B3BC0A74-08E3-4831-A97E-DFCFED657BA6Q24625558-FE19F62E-3CA2-40E4-8105-3997BD2C0EEBQ24648025-F91A61B4-7E17-4C11-953C-6F3530880530Q24803723-F03D152B-710F-47F5-B200-84794335267AQ24804188-D2E4DFCA-036F-45C3-A937-FECCC6C6B529Q27003218-33ED911B-2D8D-4F85-9560-DBA687273CC3Q28072560-851F30C7-0A67-4109-9A5B-6D27435D687EQ28086796-3B834408-559A-4A2F-9856-B1C059507F22Q30397716-5C3BFC6E-0862-488D-A7FC-0EBC5F5BA43FQ33496190-886C55F1-24B6-4987-8BFC-7922D4C8CE7CQ33755125-2D58D5A5-B468-4456-B007-DDC39CCFA5D3Q33779578-D59C9E35-C487-4AD0-A7B4-72D4E705E5E1Q33805953-088CBCF2-82A1-4AEF-86C7-B7AC3FFE0343Q33811487-AF596EF3-6471-4AD6-BADF-81B304608431Q34158474-2BD04449-D0B6-4276-8FAD-5F22AB0524F4Q34227747-4E1A7416-C053-4B37-970B-D0389CC4B1E6Q34278855-BD031A21-740F-41B0-9207-B26D48A9BA98Q34452275-ABE6A13E-FECC-48EA-A377-84DDEBE52938Q34487963-4A47D0D7-37BA-4D8E-ABBE-8F0F8DD9022CQ34541027-595DF4C1-C30C-4BE4-A462-069F4B70D281Q34756267-F0DFF9CE-338B-444E-9097-E61F0D5E2BDFQ34838226-EA07DCC4-4014-428F-9623-AAD1D582BCBFQ34866982-7DAA04D2-2BCD-417C-8AEE-759517A2ADA2Q34982783-96E71287-BBF7-4BCC-A983-082623191023Q35165927-71434286-8E57-4ECE-AF9A-A9326B915E13Q35176138-298734F4-3090-4155-B533-BDD5585866E5Q35551042-015426CE-5D8A-4A83-8537-B8D1EB914F65Q35605737-9C58235D-698F-4E00-BE9B-6E48040EB9B0Q35608000-FEF9EDB2-66D3-4989-BFC8-63A80AE1A7C4Q35622873-6D414D9E-77B1-45A5-B750-9F4C595F5919Q35740051-38C3DE8C-DD3D-406B-9258-ECAA35C75FDFQ35944627-B0F02A33-5213-4C5D-A99F-34042C48BCE1Q35971862-98F92567-FDB8-41A8-A7E2-35DF04EC7ADFQ35972768-4201B4CC-8A2E-427C-9CF7-9D86FE0EDDC2Q36463015-5BACE1F3-AD4C-4EBD-8809-DE09EB7BBAA8Q36511603-FCBF57A0-0C44-4BAB-A1BC-EC397853ADB5Q36561595-10E41BD8-5D8D-450C-9613-9822F56B297AQ36600976-80D4D7E5-7228-4F41-A295-1BC3BDACDC4D
P2860
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@en
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@nl
type
label
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@en
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@nl
prefLabel
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@en
Elevated Skp2 protein expressi ...... uced recurrence-free survival.
@nl
P2093
P1476
Elevated Skp2 protein expressi ...... duced recurrence-free survival
@en
P2093
Angelo De Marzo
Anna Frolov
Guang Yang
Gustavo Ayala
J Wade Harper
Thomas M Wheeler
Timothy C Thompson
Weihua Tian
P304
P407
P577
2002-11-01T00:00:00Z